ASX
Clarity Pharmaceuticals Ltd
CU6:ASX•Healthcare
Sensitive ASX Announcement
Phase II SABRE prostate cancer trial reaches 50% recruitment
Published: 24/07/23, 08:25am (AEST)•3 pages